| scholarly article | Q13442814 |
| P2093 | author name string | Jean-Ehrland Ricci | |
| Johanna Chiche | |||
| P2860 | cites work | Role of AMP-activated protein kinase in mechanism of metformin action | Q22241898 |
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton | Q24299873 | ||
| Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive | Q24306328 | ||
| Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1 | Q24313010 | ||
| The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1 | Q24315566 | ||
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| AMPK phosphorylation of raptor mediates a metabolic checkpoint | Q24329244 | ||
| IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway | Q24337225 | ||
| Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex | Q24559347 | ||
| Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase | Q24564747 | ||
| Understanding the Warburg effect: the metabolic requirements of cell proliferation | Q24604760 | ||
| Posttranscriptional control of T cell effector function by aerobic glycolysis | Q24606942 | ||
| A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma | Q24607479 | ||
| Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma | Q36680261 | ||
| Hypoxia signalling controls metabolic demand | Q36736651 | ||
| Metabolic switching and fuel choice during T-cell differentiation and memory development | Q36820974 | ||
| Tumorigenic activity and therapeutic inhibition of Rheb GTPase | Q36843535 | ||
| mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. | Q36843792 | ||
| Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation | Q36971030 | ||
| PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma | Q37049376 | ||
| Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. | Q37120620 | ||
| Cancer metabolism: fatty acid oxidation in the limelight | Q37155867 | ||
| mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin | Q37166913 | ||
| Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism. | Q37229088 | ||
| Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells | Q37261134 | ||
| Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. | Q37311260 | ||
| Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target | Q37596851 | ||
| Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies | Q37598141 | ||
| Adverse events associated with mTOR inhibitors | Q38068519 | ||
| Disrupting proton dynamics and energy metabolism for cancer therapy | Q38130850 | ||
| Regulation of T cells by mTOR: the known knowns and the known unknowns | Q38293289 | ||
| Glutamine transporters in mammalian cells and their functions in physiology and cancer | Q38685207 | ||
| Targeting mTOR for the treatment of B cell malignancies | Q38709825 | ||
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| Genome sequencing identifies a basis for everolimus sensitivity | Q24631915 | ||
| Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways | Q24652565 | ||
| Fundamentals of cancer metabolism | Q26744062 | ||
| Energy disruptors: rising stars in anticancer therapy? | Q26771300 | ||
| Regulation of mTORC1 by amino acids | Q27025586 | ||
| mTOR kinase structure, mechanism and regulation | Q27677954 | ||
| Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP | Q27732817 | ||
| Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics | Q27851412 | ||
| Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib | Q27852954 | ||
| A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. | Q27852958 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| TSC2 mediates cellular energy response to control cell growth and survival | Q27860970 | ||
| Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway | Q28115008 | ||
| The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway | Q28118993 | ||
| A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project | Q28239256 | ||
| Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis | Q28246808 | ||
| Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression | Q28272474 | ||
| Oncogenically active MYD88 mutations in human lymphoma | Q28301648 | ||
| Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB | Q28306356 | ||
| Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells | Q28504783 | ||
| The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4 | Q28508613 | ||
| The biology of cancer: metabolic reprogramming fuels cell growth and proliferation | Q29547301 | ||
| Regulation of TORC1 by Rag GTPases in nutrient response | Q29614478 | ||
| Activation of a metabolic gene regulatory network downstream of mTOR complex 1 | Q29615179 | ||
| Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain | Q29615210 | ||
| Molecular mechanisms of mTOR-mediated translational control | Q29615529 | ||
| Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity | Q29616651 | ||
| mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex | Q29617214 | ||
| On respiratory impairment in cancer cells | Q29617276 | ||
| Otto Warburg's contributions to current concepts of cancer metabolism | Q29617601 | ||
| Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance | Q29620462 | ||
| Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice | Q30080001 | ||
| LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells | Q30313865 | ||
| Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Q35567244 | ||
| Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo | Q35606075 | ||
| MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism | Q35669189 | ||
| Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma | Q35848973 | ||
| Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy | Q35865232 | ||
| Metabolism of [U-13 C]glucose in human brain tumors in vivo | Q36120642 | ||
| Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition | Q36169778 | ||
| PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. | Q36244792 | ||
| Pathogenesis of follicular lymphoma | Q36290288 | ||
| Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. | Q36330223 | ||
| Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma | Q36342398 | ||
| Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells | Q36369816 | ||
| Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. | Q36464689 | ||
| The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence | Q36541067 | ||
| Metabolic Heterogeneity in Human Lung Tumors. | Q36578111 | ||
| Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer | Q36669793 | ||
| Germinal Center Selection and Affinity Maturation Require Dynamic Regulation of mTORC1 Kinase. | Q50931710 | ||
| Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. | Q51189895 | ||
| B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. | Q51441965 | ||
| Adaptive remodeling of skeletal muscle energy metabolism in high-altitude hypoxia: Lessons from AltitudeOmics. | Q51740157 | ||
| Glutaminolysis activates Rag-mTORC1 signaling. | Q52301079 | ||
| Unraveling the Complex Interplay Between T Cell Metabolism and Function. | Q52314225 | ||
| Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells. | Q54109544 | ||
| mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. | Q54398394 | ||
| Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study. | Q54628402 | ||
| Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). | Q54689358 | ||
| Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. | Q55068347 | ||
| The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice | Q57338720 | ||
| Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response | Q57374967 | ||
| European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma | Q61868247 | ||
| Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides | Q62319510 | ||
| Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study | Q77218302 | ||
| PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma | Q80685308 | ||
| B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies | Q88090511 | ||
| Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. | Q38724307 | ||
| mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells | Q38780140 | ||
| Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma | Q38798340 | ||
| mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle | Q38910153 | ||
| GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α. | Q38940618 | ||
| Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer | Q39024340 | ||
| Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma | Q39127868 | ||
| PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. | Q39193337 | ||
| Metabolism. Differential regulation of mTORC1 by leucine and glutamine | Q39211265 | ||
| Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. | Q39472188 | ||
| Rituximab inhibits B-cell receptor signaling. | Q39766389 | ||
| Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma | Q39805170 | ||
| Glycolytic flux signals to mTOR through glyceraldehyde-3-phosphate dehydrogenase-mediated regulation of Rheb | Q39849826 | ||
| Mutations of the PIK3CA gene in diffuse large B cell lymphoma | Q39996055 | ||
| Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma | Q40002119 | ||
| Oncogenic CARD11 mutations in human diffuse large B cell lymphoma | Q40005246 | ||
| Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells | Q40050621 | ||
| PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma | Q40080835 | ||
| Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. | Q40183645 | ||
| Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma | Q40202733 | ||
| Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells | Q40216291 | ||
| Syk-dependent mTOR activation in follicular lymphoma cells. | Q40243215 | ||
| Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. | Q40253260 | ||
| Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. | Q40377835 | ||
| Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. | Q40507932 | ||
| Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cyt | Q40795750 | ||
| PTEN gene alterations in lymphoid neoplasms | Q41000268 | ||
| LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation | Q41412927 | ||
| Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression | Q41437712 | ||
| Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. | Q41983843 | ||
| Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 | Q42152675 | ||
| Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo | Q42198162 | ||
| PIK3CA amplification and PTEN loss in diffused large B-cell lymphoma | Q42371625 | ||
| Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors | Q42650839 | ||
| The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction | Q43863953 | ||
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
| Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res | Q45236772 | ||
| Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study | Q45259081 | ||
| Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism | Q46381905 | ||
| Lactate Metabolism in Human Lung Tumors | Q47594603 | ||
| Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma | Q47686516 | ||
| The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? | Q49478699 | ||
| As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid. | Q50033598 | ||
| mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway | Q30425628 | ||
| High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells | Q30433183 | ||
| Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation | Q30619793 | ||
| Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma | Q33366976 | ||
| Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group | Q33379949 | ||
| Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma | Q33385283 | ||
| Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study | Q33394663 | ||
| A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma | Q33399582 | ||
| Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma | Q33404317 | ||
| Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma | Q33410761 | ||
| Direct control of mitochondrial function by mTOR. | Q33552261 | ||
| Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas | Q33574190 | ||
| Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis | Q33597162 | ||
| Genetics of follicular lymphoma transformation | Q33910446 | ||
| Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis | Q34009330 | ||
| Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma | Q34104112 | ||
| Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. | Q34182185 | ||
| Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. | Q34277639 | ||
| The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation | Q34283579 | ||
| The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation | Q34308263 | ||
| Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium | Q34488779 | ||
| The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development | Q34493999 | ||
| Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. | Q34494007 | ||
| Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. | Q34506457 | ||
| Mechanism of arginine sensing by CASTOR1 upstream of mTORC1 | Q34536224 | ||
| Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era | Q34568868 | ||
| A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse la | Q34782868 | ||
| Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a). | Q34922043 | ||
| Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein | Q35046706 | ||
| HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells | Q35102340 | ||
| Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function | Q35223050 | ||
| CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors | Q35289071 | ||
| Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment | Q35408838 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 556 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies | |
| P478 | volume | 8 |
| Q90521649 | Drug Resistance in Non-Hodgkin Lymphomas |
| Q90642708 | Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation |
| Q91362446 | Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models |
| Q94561521 | Missing-in-Metastasis/Metastasis Suppressor 1 Regulates B Cell Receptor Signaling, B Cell Metabolic Potential, and T Cell-Independent Immune Responses |
| Q92905230 | Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy |
Search more.